• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    The Week in Canadian Press Releases: 10 Stories You Need to See

    9/27/24 6:18:00 AM ET
    $LSPD
    $VRTX
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LSPD alert in real time by email

    A roundup of the most newsworthy press releases from Cision Distribution this week

    TORONTO, Sept. 27, 2024 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.

    Cision Canada - The Weekly Round-Up (PRNewsfoto/Cision Canada)

    The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download.

    1. Tell 'em with Tims: Tim Hortons celebrating National Coffee Day with limited-edition hot coffee cups to share a motivational message with family and friends 

      "For many of our guests, the simple act of treating their loved ones with a Tims coffee can mean so much – and we wanted to celebrate that power of connection and kindness with limited-edition cups that we're serving in the leadup to National Coffee Day on Sept. 29," said Hope Bagozzi, Chief Marketing Officer for Tim Hortons. Available while supplies last, there are five bilingual National Coffee Day cup designs that will be randomly served to guests who order a medium hot coffee starting tomorrow, including the messages: You Got This, Cheers, Here's To You, You Do You, or XOXO.
    2. Lightspeed Commerce Responds to Media Reports 

      Lightspeed Commerce Inc. (NYSE:LSPD) (TSX: LSPD) ("Lightspeed" or the "Company"), today issued the following statement: While it is the long-standing policy of Lightspeed not to comment on market rumors, the Company notes the recent media reports concerning a potential transaction involving the Company. Lightspeed periodically undertakes, and is currently conducting, a strategic review of its business and operations with a view to realizing its full potential. In this context, the Company has engaged, and may continue to engage, in discussions relating to a range of potential strategic alternatives.
    3. Prime Video Announces Trailer and Premiere Date of FACEOFF: Inside the NHL - the Highly Anticipated Docuseries from Box To Box and NHL Productions 

      Prime Video announced the trailer and premiere date for FACEOFF: Inside the NHL (6x45), the previously untitled docuseries from Box To Box and NHL Productions. Set to premiere globally October 4 on Prime Video, the series gives unprecedented access to the National Hockey League's biggest teams and most compelling players, all at different stages of their careers, as they embark throughout the season on the ultimate pursuit of glory – winning the coveted Stanley Cup. FACEOFF: Inside the NHL joins Prime Monday Night Hockey, which will stream national regular season Monday night NHL games exclusively on Prime Video in Canada. 
    4. Royal Air Force Red Arrows Land in St. John's for the Final Stop of the Canadian Tour 

      After a series of performances flying past some of Canada's most renowned landmarks and partaking in several air shows in Halifax, Niagara Falls, Toronto, Ottawa, London, and Montreal, the Red Arrows' journey comes to a close in Newfoundland and Labrador. Maple Hawk 2024 celebrates the deep bond between Canada and the UK, offering each city a chance to engage with both nations' rich cultural and historical ties. Through partnerships with schools, training institutes and organisations such as Let's Talk Science, the tour has also offered a hands-on look at advancements in aerospace technology and STEM initiatives all to help shape research and development for future generations.
    5. New Tim Hortons Halloween collection includes glow-in-the-dark Timbits® Bucket and drinkware, plus visit TimShop.ca for Tims-themed costumes for kids and dogs! 

      This year's glow-in-the-dark Timbits Bucket features a frightfully fun design including a spooky ghost and Timbit spider. The Timbits Bucket can also be purchased with 31 Timbits to share with family and friends. Participating Tims restaurants across Canada are also offering guests a 24oz/710mL straw tumbler that glows in the dark, plus a ghost-shaped ceramic mug with heat-activated details. TimShop.ca has even more Halloween items to purchase including a Timbits Box costume for kids and a Tims-themed lumberjack costume for dogs. There's also a heat-activated Jack O'Lantern ceramic mug, and some fun ghost-themed items including a fluffy pillow, stainless steel tumbler and glow-in-the-dark straw tumbler.
    6. ROYAL CANADIAN MINT LAUNCHES NEW SINGLE MINE GOLD MAPLE LEAF BULLION COIN ENTIRELY SOURCED FROM AGNICO EAGLE'S DETOUR LAKE MINE 

      The 2024 $50 1 oz. 99.99% Pure Gold Maple Leaf Single Mine bullion coin is entirely composed of gold from Canadian mining giant Agnico Eagle's Detour Lake mine in Northern Ontario. This special gold bullion coin is now available at select Costco stores across Canada, as well as online at www.costco.ca. "The Royal Canadian Mint is known worldwide for its refining prowess and innovation, as well as its robust environmental, social and governance practices. We are proud to once more showcase the purity and responsibility of our Gold Maple Leaf bullion coin by partnering with Agnico Eagle's Detour Lake mine to issue our newest Single Mine GML coin," said Marie Lemay, President and CEO of the Royal Canadian Mint.
    7. The Iconic Pret A Manger coffee is now available at A&W restaurants nationwide

       All A&W locations in Canada are now serving Pret freshly brewed organic Classic Blend coffee all day long, offering guests a delicious and satisfying coffee experience with every visit. "Pret Coffee's exceptional quality and taste have won over coffee lovers worldwide, and we're thrilled to bring it to over 1,000 locations across Canada," says Scott Darlow, Lead, Pret A Manger at A&W Canada. "We've tested Pret coffee in select A&W locations where it quickly became a favourite among guests, which led us to make it our official coffee at all A&W restaurants. We're excited to bring this beloved coffee to more Canadians."
    8. Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia 

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced Health Canada has granted Marketing Authorization for PrCASGEVY® (exagamglogene autotemcel), an autologous genome edited hematopoietic stem cell-based therapy, for the treatment of patients 12 years of age and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). There are an estimated 2,000 patients eligible for CASGEVY in Canada, the majority of whom are living with SCD. This approval is based on the positive interim results from two global and ongoing clinical trials, CLIMB-121 in SCD and CLIMB-111 in TDT. 
    9. Elysium Investments Surpasses $200M in Acquisitions, Closing in on 4,000 Units and $3B Under Development 

      Elysium Investments Inc., a Toronto-based real estate investment and development firm, has acquired a prime 1.23-acre development site at 21-29 Oakmount Road & 26-36 Mountview Avenue, near High Park. This acquisition brings Elysium's total investments to over $200 million in just over a year. The firm is nearing 4,000 housing units and more than $3 billion in developments. The project will include two high-rise residential towers on a shared podium, providing much-needed rental housing in a transit-connected area. Elysium is partnering with Hepsor, an Estonian real estate developer, and Oikoi Living, marking their second collaboration.
    10. Alanis Obomsawin: The Children Have to Hear Another Story 

      The Musée d'art contemporain de Montréal (MAC) launched its new exhibition, Alanis Obomsawin: The Children Have to Hear Another Story, on Wednesday at the MAC at Place Ville Marie. This major retrospective, a one-of-a-kind opportunity to celebrate more than 60 years of artistic creation by this exceptional Abenaki filmmaker, singer and activist, will be open to the public until January 26, 2025, in the MAC's temporary space at Place Ville Marie. On the same day, Caroline Monnet's mural Wàbigon was also unveiled; it will be on display until February 16, 2025, at the MAC at Place Ville Marie.

    Read more of the latest releases from Cision, see our resources for journalists, and stay caught up on the top press releases by following @cnwnews.

    About Cision Canada

    Cision is a comprehensive communications platform enabling more than 100,000 public relations and marketing professionals around the world to understand, influence and amplify their stories. As the market leader, Cision enables the next generation of communication professionals to strategically operate in the modern media landscape where company success is directly impacted by public opinion. Cision has offices in 24 countries through the Americas, EMEA and APAC, and offers a suite of best-in-class solutions, including Newswire, Brandwatch, Cision Communications Cloud® and Cision Insights. To learn more, visit www.cision.ca and follow @CisionCA on Twitter.

    Cision logo

    SOURCE Cision Canada

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2024/27/c5009.html

    Get the next $LSPD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LSPD
    $VRTX

    CompanyDatePrice TargetRatingAnalyst
    Vertex Pharmaceuticals Incorporated
    $VRTX
    3/10/2026$580.00Buy
    Jefferies
    Vertex Pharmaceuticals Incorporated
    $VRTX
    3/10/2026$540.00 → $600.00Outperform
    Oppenheimer
    Vertex Pharmaceuticals Incorporated
    $VRTX
    2/13/2026$540.00Perform → Outperform
    Oppenheimer
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/28/2026$606.00Overweight
    Barclays
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/22/2026$546.00Sector Perform → Outperform
    RBC Capital Mkts
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/12/2026Mkt Perform → Outperform
    Bernstein
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/7/2026$535.00Buy
    UBS
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/6/2026$548.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $LSPD
    $VRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Commercial Officer Mckechnie Duncan sold $1,312,340 worth of shares (2,633 units at $498.42), decreasing direct ownership by 17% to 12,489 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    3/13/26 4:11:50 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Commercial Officer Mckechnie Duncan sold $1,158,306 worth of shares (2,437 units at $475.30), decreasing direct ownership by 14% to 15,122 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    3/6/26 4:05:56 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP and Chief Legal Officer Liu Joy sold $442,396 worth of shares (892 units at $495.96), decreasing direct ownership by 4% to 22,811 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    3/4/26 4:21:16 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LSPD
    $VRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Vertex Pharma with a new price target

    Jefferies initiated coverage of Vertex Pharma with a rating of Buy and set a new price target of $580.00

    3/10/26 8:43:03 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer reiterated coverage on Vertex Pharma with a new price target

    Oppenheimer reiterated coverage of Vertex Pharma with a rating of Outperform and set a new price target of $600.00 from $540.00 previously

    3/10/26 8:19:07 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex Pharma upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Vertex Pharma from Perform to Outperform and set a new price target of $540.00

    2/13/26 7:53:31 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LSPD
    $VRTX
    SEC Filings

    View All

    SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

    144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    2/27/26 9:50:34 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

    144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    2/18/26 12:28:45 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

    144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    2/18/26 10:46:41 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LSPD
    $VRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

    For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

    1/30/25 5:46:14 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

    Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling

    8/4/23 4:36:00 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LSPD
    $VRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $LSPD
    $VRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lightspeed Launches Mobile Tap in Quebec, Expanding Tableside Payment Flexibility

    MONTREAL, March 16, 2026 /CNW/ - Lightspeed Commerce Inc. (NYSE:LSPD) (TSX:LSPD) ("Lightspeed" or the "Company"), the unified omnichannel platform powering ambitious retail, golf and hospitality businesses in over 100 countries, today announced the launch of Mobile Tap in Quebec, the newest addition to its Lightspeed Tableside solution. As restaurants face labour pressures and increasing guest expectations for speed and convenience, Mobile Tap enables staff to take orders and securely accept payments anywhere in the venue, without the need to return to a fixed terminal. Designed

    3/16/26 8:00:00 AM ET
    $LSPD
    Computer Software: Prepackaged Software
    Technology

    Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

    - For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a statistically significant and clinically meaningful 49.8% reduction in UPCR versus placebo (P<0.0001) – - For the first secondary endpoint, povetacicept treatment led to a 77.4% reduction from baseline in serum Gd-IgA1, resulting in a statistically significant and clinically meaningful reduction of 79.3% (P<0.0001) versus placebo; for the second secondary endpoint, 85.1% of povetacicept-treated patients achieved hematuria resolution, resulting in a statistically significant and clinically meani

    3/9/26 4:02:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex to Participate in Upcoming March Investor Conferences

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, and Duncan McKechnie, Chief Commercial Officer, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026, at 10:00 a.m. ET. Susie Lisa, Senior Vice President, Investor Relations, and Miroslava Minkova, Executive Director, Investor Relations, will participate in a fireside chat at the Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026, at 11:30 a.m. ET. About Vertex Vertex is a global biotechnology company that invests in s

    3/5/26 4:00:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Kewalramani Reshma bought $3,895,768 worth of shares (10,000 units at $389.58), increasing direct ownership by 9% to 115,968 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    8/7/25 4:23:31 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sachs Bruce I bought $1,948,416 worth of shares (5,000 units at $389.68), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    8/7/25 4:19:03 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LSPD
    $VRTX
    Leadership Updates

    Live Leadership Updates

    View All

    Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

    Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer ("CDO") and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals (NASDAQ:VRTX). She joins Satellos from Generation Bio (NASDAQ:G

    1/29/26 7:00:00 AM ET
    $GBIO
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Freshworks Appoints Kady Srinivasan as Chief Marketing Officer

    SAN MATEO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Freshworks (NASDAQ:FRSH), today announced Kady Srinivasan has joined as its Chief Marketing Officer, bringing over 15 years of leadership experience driving large-scale marketing transformations at high-growth SaaS companies. Srinivasan will lead Freshworks' global marketing strategy to amplify the company's mission to deliver exceptional customer and employee experiences with uncomplicated service software. Srinivasan will report to Mika Yamamoto, who serves as Freshworks' Chief Integrated Customer Growth Officer, and continues to oversee Marketing, Customer Support, and the Small Business and Commercial Sales and Customer Success organ

    1/7/26 8:00:00 AM ET
    $FRSH
    $LSPD
    Computer Software: Prepackaged Software
    Technology

    Lightspeed Appoints Industry Veteran Gabriel Benavides as Chief Revenue Officer to Accelerate Profitable Growth

    MONTREAL, Nov. 13, 2025 /PRNewswire/ - Lightspeed Commerce Inc. (NYSE:LSPD) (TSX:LSPD) ("Lightspeed" or the "Company"), the unified commerce platform powering ambitious retailers and restaurateurs in over 100 countries, today announced the appointment of Gabriel Benavides as Chief Revenue Officer (CRO). This leadership evolution aligns with Lightspeed's transformation into a focused, high-efficiency growth company and supports its strategy to drive sustained, profitable expansion across its markets. As CRO, Benavides will oversee global revenue generation, aligning sales, cust

    11/13/25 7:00:00 AM ET
    $LSPD
    Computer Software: Prepackaged Software
    Technology

    $LSPD
    $VRTX
    Financials

    Live finance-specific insights

    View All

    Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

    — Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion, a 10% increase compared to fourth quarter 2024 — — Company provides full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, with non-CF products expected to contribute $500 million or more in revenue — — Broad mid- and late-stage clinical pipeline accelerates with multiple proof-of-concept and pivotal programs advancing; on track to complete BLA filing for U.S. accelerated approval of povetacicept in IgAN in the first half of 2026 — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the f

    2/12/26 4:01:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lightspeed Announces Third Quarter 2026 Financial Results and Raises Fiscal 2026 Outlook

    Revenue of $312.3 million exceeded outlook Gross profit margins improved to 43% with gross profit increasing 15% year-over-year  Positive cash flow from operating activities of $28.9 million, and Adjusted Free Cash Flow1 of $14.9 million Across retail in North America and hospitality in Europe: Revenue grew 21% year-over year, GTV grew 16% year-over-year and ~2,600 net Customer Locations were added in the quarter Lightspeed reports in US dollars and in accordance with IFRS Accounting Standards. MONTREAL, Feb. 5, 2026 /PRNewswire/ - Lightspeed Commerce Inc. (NYSE:LSPD) (TSX:LSPD) ("Lightspeed" or the "Company"), the unified omnichannel platform powering ambitious retail and hospitality busin

    2/5/26 7:00:00 AM ET
    $LSPD
    Computer Software: Prepackaged Software
    Technology

    Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Fourth Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled web

    1/20/26 4:00:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LSPD
    $VRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

    SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    4/10/24 12:14:10 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lightspeed Commerce Inc. Subordinate Voting Shares (Amendment)

    SC 13G/A - Lightspeed Commerce Inc. (0001823306) (Subject)

    3/11/24 8:16:53 AM ET
    $LSPD
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Lightspeed Commerce Inc. Subordinate Voting Shares (Amendment)

    SC 13G/A - Lightspeed Commerce Inc. (0001823306) (Subject)

    2/13/24 9:00:13 PM ET
    $LSPD
    Computer Software: Prepackaged Software
    Technology